Lineage Cell Therapeutics Inc (AMEX: LCTX) on Friday, soared 17.65% from the previous trading day, before settling in for the closing price of $1.02. Within the past 52 weeks, LCTX’s price has moved between $0.37 and $1.21.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -2.93% over the last five years. The company achieved an average annual earnings per share of -111.11%. With a float of $227.36 million, this company’s outstanding shares have now reached $228.36 million.
The firm has a total of 77 workers. Let’s measure their productivity. In terms of profitability, gross margin is 72.58%, operating margin of -322.84%, and the pretax margin is -374.33%.
Lineage Cell Therapeutics Inc (LCTX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Lineage Cell Therapeutics Inc is 0.44%, while institutional ownership is 43.20%. The most recent insider transaction that took place on Jan 27 ’25, was worth 6,000,000. In this transaction Director of this company bought 7,894,737 shares at a rate of $0.76, taking the stock ownership to the 49,560,992 shares. Before that another transaction happened on Nov 26 ’24, when Company’s Chief Financial Officer bought 15,000 for $0.59, making the entire transaction worth $8,850. This insider now owns 25,500 shares in total.
Lineage Cell Therapeutics Inc (LCTX) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.02 earnings per share (EPS) for the period topping the consensus outlook (set at -0.03) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -111.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.25% during the next five years compared to -2.93% drop over the previous five years of trading.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Lineage Cell Therapeutics Inc (LCTX) is currently performing well based on its current performance indicators. A quick ratio of 4.08 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 25.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.18, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.07 in one year’s time.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Analysing the last 5-days average volume posted by the [Lineage Cell Therapeutics Inc, LCTX], we can find that recorded value of 2.33 million was better than the volume posted last year of 1.93 million. As of the previous 9 days, the stock’s Stochastic %D was 73.90%.
During the past 100 days, Lineage Cell Therapeutics Inc’s (LCTX) raw stochastic average was set at 88.36%, which indicates a significant increase from 69.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0852 in the past 14 days, which was higher than the 0.0662 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9636, while its 200-day Moving Average is $0.6802. Now, the first resistance to watch is $1.3302. This is followed by the second major resistance level at $1.4604. The third major resistance level sits at $1.6108. If the price goes on to break the first support level at $1.0496, it is likely to go to the next support level at $0.8992. Now, if the price goes above the second support level, the third support stands at $0.7690.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Key Stats
Market capitalization of the company is 274.03 million based on 228,356K outstanding shares. Right now, sales total 9,500 K and income totals -18,610 K. The company made 1,500 K in profit during its latest quarter, and -4,140 K in sales during its previous quarter.
